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of all anti-VapA speciﬁc IgG concentrations (Table 1). When anti-
VapA speciﬁc IgG concentrations were compared between the
dam’s serum, R. equi HIP, and foal’s serum, either weak positive
or negative linear correlations were observed (-0.15 < r < 0.20),
with the exception of IgG(t), which showed a moderate positive
linear correlation between R. equi speciﬁc HIP, and foal’s serum
(r ¼ 0.71). Our results revealed an even greater variation in anti-
VapA speciﬁc IgG concentrations within and among the different
lots of the selected R. equi HIP product, than previously reported.
This ﬁnding may corroborate in explaining historical disparities
regarding R. equi speciﬁc HIP efﬁcacy in preventing R. equi
pneumonia in foals. The lack of a positive correlation between
the anti-VapA speciﬁc IgG concentrations between the dams,
HIP and the recipient foals is not fully understood. However,
possible explanations include suboptimal time sampling of the
dams, low anti-VapA speciﬁc IgG concentrations in adult horses,
and unknown antibody kinetics of the anti-VapA speciﬁc IgGs in
the recipient foal. Recently, it has been reported that after
intravenous administration of R. equi HIP, the concentrations of
anti-VapA speciﬁc IgGs in the bronchoalveolar ﬂuid increases,
suggesting compartmentalization of these antibodies outside
the systemic circulation. The moderate positive correlation
observed between the concentrations of IgG(t) between the R.
equi HIP and the recipient foals was likely due to its high con-
centration in the HIP product. Serial measurements of the foal’s
serum concentrations of anti-VapA speciﬁc IgGs is warranted in
order to evaluate their relationship with clinical disease, and
therefore the efﬁcacy of this commercially available R. equi HIP
in preventing naturally acquired pneumonia in foals.Table 1
Intra- and inter-lot coefﬁcient of variation (CV) of anti-VapA speciﬁc IgG
concentrations in different lots of R. equi HIP1.
CV(%)
Lot # IgG total IgGa IgGb IgGt
1 49.39 51.74 54.50 32.79
2 45.02 57.73 32.89 28.15
3 58.52 63.38 55.71 39.15
4 57.81 65.87 59.07 58.03
5* - - - -
6 39.18 55.54 46.33 47.53
7 60.43 61.40 59.22 58.09
8 70.83 91.88 79.37 31.83
9 51.96 56.79 71.16 52.33
10* - - - -
11* - - - -
All lots 60.88 62.70 87.63 90.97* Only one HIP bag was sampled.
Reference
[1] ImmunoGlo, MgBiologics, Aimes, Iowa, USA.
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Bronchopneumonia caused by Rhodococcus equi is an important
and often debilitating disease of young horses throughout the
world. Advances in diagnostic methods for the early detection
of lung lesions, such as ultrasonographic imaging, have been
associated with an increase in the use of antimicrobial agents
for the treatment of this disease. Concurrent with this increased
usage, reports of antimicrobial resistance in R. equi have
become more common in recent years. The aim of this study
was to determine the level of resistance to three commonly
prescribed antimicrobial agents in 97 virulent Rhodococcus equi
isolates collected from infected foals between 1991 and 2014.
The second objective was to determine the utility of a novel
assay for determining the minimum inhibitory concentration
(MIC) of R. equi isolates with a single agent, or when rifampicin
and erythromycin were combined. Three cohorts of virulent
Rhodococcus equi isolates were included in the study. Cohort 1
contained 29 isolates collected from clinical cases between
1991 and 1998 and Cohort 2 consisted of 12 recent isolates
collected between 2011 and 2014. Fifty six isolates from clini-
cally affected foals undergoing antimicrobial therapy in 2006 -
2007 on an endemically infected farm formed Cohort 3. The
MICs for rifampicin, erythromycin and neomycin were deter-
mined for all of the isolates using a novel microtitre assay.
Rifampicin resistance was detected in 3 of the 12 isolates in
Cohort 2. The MIC was 64 mg/mL for two of the isolates and 16
mg/mL for the third, well above the threshold of 8 mg/mL that
deﬁnes resistance to this agent. All isolates collected prior to
2013 had MICs less than 0.125 mg/mL (limit of detection). None
of the isolates were resistant to either neomycin or erythro-
mycin, with MIC values ranging from 0.25 - 2 mg/mL for
neomycin and 0.125 - 1 mg/mL for erythromycin. When rifam-
picin and erythromycin were tested in combination, the MIC
value for the isolates resistant to rifampicin were lower,
compared to exposure to rifampicin alone. This is the ﬁrst
report of rifampicin resistance in virulent R. equi isolated from
Australian foals. Sanger sequencing of a portion of the RNA
polymerase b subunit was conducted to further characterise the
resistant isolates from Cohort 2 [1], [2]. The current therapeutic
success of the macrolide - rifampicin combination regimen is
thought to rely on the synergistic action of these two agents in
vivo. It is not clear from these results whether the rifampicin
resistance we have detected has any signiﬁcant impact on
synergy in vivo.References
[1] Fines et al. (2001) J. Clin Micro 39(8): 2784-7.
[2] Zaczek et al. (2009) BMC Micro 9:10.
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